Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
NCT ID NCT07767799
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adults receiving these therapies as part of routine care, and analyze genetic, immune, and metabolic features. The goal is to find patterns that could help doctors personalize treatment and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Novel monoclonal antibodies (including bispecific antibodies, immunoconjugates, and naked antibodies) used as standard-of-care treatment
- What this could lead to
- If successful, this could help doctors predict which lymphoma patients will respond best to antibody therapies, potentially guiding more personalized treatment decisions.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients or treatments, and the biomarkers studied may not reliably predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dipartimento di Medicina Traslazionale e di Precisione - Istituto Ematologia - Policlinico Umberto I - Università "La Sapienza" - Roma
Roma, 00161, Italy
-
Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di Aviano
Aviano, 33081, Italy
-
Ematologia - ASST Spedali Civili di Brescia
Brescia, 25123, Italy
-
Ematologia - Arcispedale Santa Maria Nuova - IRCCS -Azienda Unità Sanitaria Locale
Reggio Emilia, 42123, Italy
-
Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, 20133, Italy
-
Ematologia - Fondazione del Piemonte per l'Oncologia - IRCCS
Candiolo, Torino, 10060, Italy
-
Ematologia - Ospedale S. Bortolo - ULSS 8 Berica
Vicenza, 36100, Italy
-
Ematologia Universitaria - A.O.U. Città della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Istituto di Ematologia "Seragnoli" - Policlinico S.Orsola-Malpighi
Bologna, 40138, Italy
-
Oncoematologia IOV - Ospedale di Castelfranco Veneto
Castelfranco Veneto, Treviso, 31033, Italy
-
S.C. Ematologia - A.O. S. Croce e Carle
Cuneo, 12100, Italy
-
S.C. Ematologia - A.O.U. Città della Salute e della Scienza di Torino
Torino, 10126, Italy
-
SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
SC Ematologia - Azienda Ospedaliera Papa Giovanni XXIII - Bergamo
Bergamo, 24127, Italy
-
SCDU Ematologia - AOU Maggiore della Carità di Novara
Novara, 28100, Italy
-
SCDU Ematologia -AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Alessandria, 15121, Italy
-
U.O. Ematologia - AOU Integrata di Verona
Verona, 37134, Italy
-
U.O.C Ematologia - IRCCS Istituto Tumori Giovanni Paolo II - Bari
Bari, 70124, Italy
-
UOC Ematologia Dipartimento Oncologico Ematologico - P.O. Spirito Santo di Pescara - ASL Pescara
Pescara, 65124, Italy
-
Unità funzionale di Ematologia -Azienda Ospedaliera Universitaria Careggi
Florence, 50141, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.